Changes over calendar time in the risk of specific first AIDS-defining events following HIV seroconversion, adjusting for competing risks.
暂无分享,去创建一个
Anne M Johnson | V. Beral | J. Kaldor | N. Day | P. Vanhems | R. Brettle | O. Kirk | P. Francioli | C. Sabin | A. Phillips | D. De Angelis | A. Hatzakis | F. Dabis | M. Prins | J. Darbyshire | Christine A. Lee | F. Tyrer | P. Pezzotti | L. Meyer | G. Touloumi | A. Eskild | G. Rezza | O. Hamouda | R. Thiébaut | S. Pérez-Hoyos | L. Ashton | A. Babiker | B. van Benthem | R. Coutinho | J. del Romero | K. Porter | F. Boufassa | D. Cooper | M. Sannes | M. Rickenbach | O. Katsarou | R. Muga | J. Del Amo | J. Vizzard | N. Gill | J. Bruun | A. Karafoulidou | S. Walker | K. Fischer | M. Egger | A. Johnson | Sylvie Lawson-Aye | C. Pederson | I. Hernández Aguado | David Cooper
[1] O. Kirk,et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. , 2001, Blood.
[2] A Muñoz,et al. Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. , 2001, American journal of epidemiology.
[3] C. Sabin. The relationships between the HIV test interval, demographic factors and HIV disease progression , 2001, Epidemiology and Infection.
[4] J. Margolick,et al. Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis , 2001, AIDS.
[5] A. Mocroft,et al. AIDS across Europe, 1994–98: the EuroSIDA study , 2000, The Lancet.
[6] S. Gange,et al. Distinguishing efficacy, individual effectiveness and population effectiveness of therapies. , 2000, AIDS.
[7] Hiv Survival,et al. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.
[8] Kholoud Porter,et al. Survival after introduction of HAART in people with known duration of HIV-1 infection , 2000, The Lancet.
[9] R. Chaisson,et al. Natural history of HIV infection in the era of combination antiretroviral therapy. , 1999, AIDS.
[10] P Pezzotti,et al. Temporal changes in the rate of progression to death among Italians with known date of HIV seroconversion: estimates of the population effect of treatment. Italian HIV Seroconversion Study (ISS). , 1999, Journal of acquired immune deficiency syndromes.
[11] A. Telenti,et al. Risk of HIV related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study , 1999, BMJ.
[12] Robert Gray,et al. A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .
[13] B. Yip,et al. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[14] JD Lundgren,et al. Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.
[15] A Muñoz,et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. , 1998, JAMA.
[16] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[17] Manuel Battegay,et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study , 1997, BMJ.
[18] A. Muñoz,et al. Models for the incubation of AIDS and variations according to age and period. , 1996, Statistics in medicine.
[19] D. Clayton,et al. Statistical Models in Epidemiology , 1993 .
[20] Niels Keiding,et al. Statistical Models Based on Counting Processes , 1993 .
[21] M. T. Paixão,et al. Expanded European AIDS case definition , 1993, The Lancet.
[22] J. Kalbfleisch,et al. The Statistical Analysis of Failure Time Data , 1980 .
[23] Tx Station. Stata Statistical Software: Release 7. , 2001 .
[24] L. J. Wei,et al. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions , 1989 .
[25] D. Cox. Regression Models and Life-Tables , 1972 .
[26] H. L. Le Roy,et al. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability; Vol. IV , 1969 .
[27] P. J. Huber. The behavior of maximum likelihood estimates under nonstandard conditions , 1967 .